Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction Study of Intravenous Cocaine and Oral SXC-2023
NCT06343532Phase 1Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cocaine use disorder (CUD) comparing SXC-2023 with SXC-2023 Placebo (2 arms). Primary endpoints: Total Number of Treatment-Emergent Adverse Events, Maximum Pulse (After 20 mg i.v. Cocaine) and 5 more. Started Oct 2024; status: completed.
02
Drugs
SXC-2023
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT06343532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343532.